You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業-B(09939.HK):福瑞他恩治療雄激素性脱髮美國II臨試完成首例患者入組及給藥
格隆匯 03-01 17:48

格隆匯3月1日丨開拓藥業-B(09939.HK)發佈公吿,其自主研發、潛在全球同類首創的福瑞他恩(KX-826)治療男性雄激素性脱髮(AGA)的美國II期臨牀試驗已於2022年2月28日完成首例受試者入組及給藥。

根據披露,該II期臨牀試驗是一項隨機、雙盲、安慰劑對照、平行分組研究,計劃入組120例受試者,旨在探索福瑞他恩在治療男性雄激素性脱髮受試者時的有效性和安全性。臨牀試驗的主要終點為於24週末,與安慰劑組相比,目標區域內非毳毛數量對比基線的變化。

此外,福瑞他恩治療AGA的中國臨牀試驗也在推進。於2021年12月31日完成男性III期試驗的首例受試者入組,試驗有26家中心參與。於2021年11月12日完成女性II期試驗的首例受試者入組。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account